Quantcast

Latest Psoriasis Stories

2014-04-09 08:29:57

DUBLIN, April 9, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/stldww/global_psoriasis) has announced the addition of the "Global Psoriasis Therapeutics Market" [http://www.researchandmarkets.com/research/stldww/global_psoriasis ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 4.06 percent over the...

2014-04-04 12:27:14

FLINT, Mich., April 4, 2014 /PRNewswire-iReach/ -- Diplomat has announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla® was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. Diplomat...

2014-03-27 12:29:39

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5sfksl/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Psoriasis - Plaque Psoriasis & Psoriatic Arthritis - Novel Oral Drugs And Biologics To Change Future Treatment Paradigm" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and...

2014-03-24 08:28:42

Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab DENVER, March 24, 2014 /PRNewswire/ -- New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal at week 16, the...

2014-03-22 08:21:21

- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2) EAST HANOVER, N.J., March 22, 2014 /PRNewswire/ -- Novartis today announced results from the Phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response...

2014-03-21 12:22:51

CANTERBURY, England, March 21, 2014 /PRNewswire/ -- - Phase 2b data demonstrates a 60% reduction in pruritus in psoriatic patients treated with CT327 - Data analysis also published in the Journal of the American Academy of Dermatology - Phase 2b CT327 topline data in patients with Atopic Dermatitis and Pruritus due in mid-2014 Creabilis Ltd, the dermatology company with the most advanced targeted topical...

2014-03-20 08:29:06

NORTH CHICAGO, Ill., March 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, an area of unmet need. Currently there are no approved treatments for fingernail psoriasis. "Since treatment options are limited, we welcome research that evaluates new options for patients suffering...

2014-03-19 23:04:29

Psoriasis Free For Life made by Katy Wilson is a newly updated psoriasis treatment program includes natural and safe remedies for reducing symptoms of psoriasis disease. A full review on the site Vkool.com indicates if it is a good product. Seattle, WA (PRWEB) March 19, 2014 Psoriasis is a chronic inflammatory skin disease that affects the life cycle of skin cells. It causes cells to build up quickly on the surface of the skin. It also forms thick silvery scales and dry, itchy and red...

2014-03-18 16:25:03

Cloud-based training collaboration delivers clinically relevant information anywhere. CONSHOHOCKEN, Pa., March 18, 2014 /PRNewswire/ -- The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and ePharmaSolutions, a leading clinical services and eClinical solutions provider, today announced their partnership to build and deliver online learning courses to clinicians working in psoriasis (PsO) and psoriatic arthritis (PsA) research and development. Via...

2014-03-12 23:01:43

TriDerma’s Facial Redness Repair™ and Psoriasis Control™ Products are now available at Target stores throughout California. Safe and effective relief for psoriasis and rosacea sufferers without harmful drugs. ANAHEIM, CA (PRWEB) March 12, 2014 TriDerma, a leading provider in medical strength skin care products based in Anaheim, California, is pleased to announce its Facial Redness Repair™ and Psoriasis Control™ Skin Healing Creams are now available in California Target stores....


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'